Software Resilience | Explore SLP's robust software segment, showcasing 8% organic growth and a 10% increase in average revenue per customer, highlighting its essential role in pharmaceuticals |
Service Sector Challenges | Delve into the headwinds facing SLP's service segment, including client-driven delays and a significant contract cancellation impacting revenue forecasts |
Strategic Positioning | Learn how SLP maintains a competitive edge with its comprehensive software suite, trading at a premium compared to competitors despite recent market challenges |
Future Prospects | Discover SLP's revised outlook, with analyst price targets ranging from $28 to $41 per share, and potential opportunities arising from evolving FDA regulations |
Metrics to compare | SLP | Peers Peers - average of corresponding metrics from companies closely matching SLP: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipSLPPeersSector |
|---|---|---|---|---|
P/E Ratio | 46.2x | 0.0x | −0.3x | |
PEG Ratio | 0.41 | 0.00 | 0.00 | |
Price/Book | 2.7x | 0.0x | 2.6x | |
Price / LTM Sales | 4.6x | 0.0x | 2.9x | |
Upside (Analyst Target) | −6.8% | 0.0% | 65.5% | |
Fair Value Upside | Unlock | 0.0% | 9.5% | Unlock |